192 related articles for article (PubMed ID: 8882031)
21. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.
Mok CC; Ying KY; Ng WL; Lee KW; To CH; Lau CS; Wong RW; Au TC
Am J Med; 2006 Apr; 119(4):355.e25-33. PubMed ID: 16564783
[TBL] [Abstract][Full Text] [Related]
22. [Assessment on intermittent intravenous cyclophosphamide pulse therapy in diffuse proliferative lupus nephritis].
Okubo T; Ideguchi H; Ihata A; Nakamura M; Ueda A; Ohno S; Hagiwara E; Aoki A; Shirai A; Ishigatsubo Y
Ryumachi; 2000 Jun; 40(3):605-11. PubMed ID: 10920685
[TBL] [Abstract][Full Text] [Related]
23. Outcome of protein-losing gastroenteropathy in systemic lupus erythematosus treated with prednisolone and azathioprine.
Mok CC; Ying KY; Mak A; To CH; Szeto ML
Rheumatology (Oxford); 2006 Apr; 45(4):425-9. PubMed ID: 16234272
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus.
Ward MM; Marx AS; Barry NN
J Rheumatol; 2000 Mar; 27(3):664-70. PubMed ID: 10743805
[TBL] [Abstract][Full Text] [Related]
25. Intermittent intravenous pulse cyclophosphamide treatment in systemic lupus erythematosus.
Malaviya AN; Singh RR; Sindhwani R; Singh YN; Ahujà RK; Bhuyan UN; Khare SD; Kumar A; Malaviya R; Negi PC
Indian J Med Res; 1992 Apr; 96():101-8. PubMed ID: 1428048
[TBL] [Abstract][Full Text] [Related]
26. Favorable response to intravenous methylprednisolone and cyclophosphamide in children with severe neuropsychiatric lupus.
Baca V; Lavalle C; García R; Catalán T; Sauceda JM; Sánchez G; Martínez I; Ramírez ML; Márquez LM; Rojas JC
J Rheumatol; 1999 Feb; 26(2):432-9. PubMed ID: 9972981
[TBL] [Abstract][Full Text] [Related]
27. Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis.
Danieli MG; Palmieri C; Salvi A; Refe MC; Strusi AS; Danieli G
J Clin Apher; 2002; 17(2):72-7. PubMed ID: 12210709
[TBL] [Abstract][Full Text] [Related]
28. Methotrexate therapy in childhood systemic lupus erythematosus.
Abud-Mendoza C; Sturbaum AK; Vazquez-Compean R; Gonzalez-Amaro R
J Rheumatol; 1993 Apr; 20(4):731-3. PubMed ID: 8496874
[TBL] [Abstract][Full Text] [Related]
29. Dexamethasone cyclophosphamide pulse therapy in systemic lupus erythematosus: a case report.
Gupta R; Gupta S; Khera V
J Dermatolog Treat; 2009; 20(1):55-8. PubMed ID: 18618362
[TBL] [Abstract][Full Text] [Related]
30. Ongoing immunologic activity after short courses of pulse cyclophosphamide in the NZB/W murine model of systemic lupus erythematosus.
Austin HA; Patel AD; Cadena CA; Boumpas DT; Balow JE
J Rheumatol; 1997 Jan; 24(1):61-8. PubMed ID: 9002012
[TBL] [Abstract][Full Text] [Related]
31. [Laboratory and morphologic parameters in patients with lupus nephritis].
Rasković S; Bogić M; Perić-Popadić A; Stefanović L; Arandjelović S; Jovicić Z; Bolpacić J; Tomić-Spirić V
Srp Arh Celok Lek; 2002 Aug; 130 Suppl 3():38-41. PubMed ID: 12583312
[TBL] [Abstract][Full Text] [Related]
32. Effective treatment of young patients with pediatric-onset, long-standing lupus nephritis with tacrolimus given as a single daily dose: an open-label pilot study.
Tanaka H; Oki E; Tsugawa K; Nonaka K; Suzuki K; Ito E
Lupus; 2007; 16(11):896-900. PubMed ID: 17971363
[TBL] [Abstract][Full Text] [Related]
33. Clinical effects of intermittent, intravenous cyclophosphamide in severe systemic lupus erythematosus.
Martinelli R; Pereira LJ; Santos ES; Rocha H
Nephron; 1996; 74(2):313-7. PubMed ID: 8893147
[TBL] [Abstract][Full Text] [Related]
34. Ovarian failure and flares of systemic lupus erythematosus.
Mok CC; Wong RW; Lau CS
Arthritis Rheum; 1999 Jun; 42(6):1274-80. PubMed ID: 10366122
[TBL] [Abstract][Full Text] [Related]
35. [Role of gonadotropin releasing hormone analogues for ovarian protection in systemic lupus erythematosus patients treated with cyclophosphamide].
Liang LQ; Qiu Q; Yang XY; Xu HS; Ye YJ; Zhan ZP; Lian F; Chen DY
Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(15):1009-11. PubMed ID: 18754430
[TBL] [Abstract][Full Text] [Related]
36. [Treatment of systemic diseases with pulse cyclophosphamide: 15 cases].
Amoura Z; Choukroun G; Royer I; Gayraud M; Guillevin L
Ann Med Interne (Paris); 1990; 141(5):416-20. PubMed ID: 2256584
[TBL] [Abstract][Full Text] [Related]
37. Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus.
Ioannidis JP; Katsifis GE; Tzioufas AG; Moutsopoulos HM
J Rheumatol; 2002 Oct; 29(10):2129-35. PubMed ID: 12375322
[TBL] [Abstract][Full Text] [Related]
38. [Risk factors of ovarian failure in the patients with systemic lupus erythematosus receiving cyclophosphamide therapy].
Yang XY; Zhu X; Liang LQ; Zhan ZP; Ye YJ
Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):960-2. PubMed ID: 16061002
[TBL] [Abstract][Full Text] [Related]
39. Can the urine dipstick test reduce the need for microscopy for assessment of systemic lupus erythematosus disease activity?
Chan RW; Chow KM; Tam LS; Li EK; Wong SM; Li PK; Szeto CC
J Rheumatol; 2005 May; 32(5):828-31. PubMed ID: 15868617
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.
Aringer M; Graninger WB; Steiner G; Smolen JS
Arthritis Rheum; 2004 Oct; 50(10):3161-9. PubMed ID: 15476222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
